MNOV Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 12:08):

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States...

Stats
Today's Volume	1 121.00
Average Volume	51 301.00
Market Cap	65.26M
EPS	$0 ( 2024-02-15 )
Next earnings date	( $-0.0500 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.83
ATR14	$0.0170 (1.28%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-09	Obrien Geoffrey	Buy	84 000	Employee Stock Option (Right to Buy)
2024-01-09	Matsuda Kazuko	Buy	157 500	Employee Stock Option (Right to Buy)
2024-01-09	Iwaki Yuichi	Buy	210 000	Employee Stock Option (Right to Buy)
2023-08-04	Lemerond Nicole	Buy	18 333	Stock Option (Right to Buy)
2023-08-04	Lemerond Nicole	Buy	0

INSIDER POWER
98.72
Last 93 transactions
Buy: 6 161 551 \| Sell: 1 269 768

MediciNova Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

MediciNova Inc Financials

Annual	2023
Revenue:	$1.00M
Gross Profit:	$979 705 (97.97 %)
EPS:	$-0.170

Q3	2023
Revenue:	$0
Gross Profit:	$-5 492.00 (0.00 %)
EPS:	$-0.0420

Q2	2023
Revenue:	$1.00B
Gross Profit:	$999.99M (100.00 %)
EPS:	$-0.0147

Q2	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.0586

Financial Reports:

No articles found.

MediciNova Inc

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.